Navigation Links
CTI Announces New Data Presented at EHA 2013 Congress Demonstrating the Safety and Tolerability Profile of Pacritinib in Patients with Myelofibrosis
Date:6/17/2013

SEATTLE, June 17, 2013 /PRNewswire/ -- Cell Therapeutics, Inc. (CTI) (NASDAQ and MTA: CTIC) today announced results from a pooled analysis of data from completed Phase 1 and 2 studies of pacritinib, an oral JAK2/FLT3 inhibitor, demonstrating the safety and tolerability profile of pacritinib in patients with myelofibrosis. An integrated safety analysis of four completed Phase 1 and 2 studies totaled 191 patients who were treated with pacritinib for myeloid, primarily myelofibrosis, or lymphoid malignancies to quantify clinical toxicities, with a focus on hematologic effects. Other JAK2 inhibitors have generally been associated with increases in anemia and thrombocytopenia but this was not observed with pacritinib. This integrated safety data analysis showed that, regardless of initial platelet counts, pacritinib causes minimal further marrow suppression. Even patients with initial platelet counts <50,000/µL, a high-risk population, tolerated therapy, maintained stable blood and platelet counts and did not require dose reductions for thrombocytopenia. Grade 1 or 2 gastrointestinal events, particularly diarrhea, were the most common adverse events and may be controlled by early administration of standard anti-diarrheal agents. The analysis was presented during a poster session at the 18th Congress of the European Hematology Association (EHA) held June 13-16, 2013 in Stockholm, Sweden. 

Pacritinib is currently being evaluated in a randomized Phase 3 clinical trial, known as PERSIST-1, in patients with myelofibrosis. Because of pacritinib's relative lack of bone marrow suppression, there are no study entry restrictions due to thrombocytopenia or anemia and patients with platelet and red blood cell transfusion dependence are allowed to enroll in the ongoing PERSIST-1 trial. More details on this study can be found at www.clinicaltrials.gov. Pa
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Zimmer Announces Quarterly Dividend for Second Quarter of 2013
2. Uroplasty Announces Delay in Filing Form 10-K
3. Cempra Announces Proposed Public Offering of Common Stock
4. Omthera Pharmaceuticals Announces Record Date and Meeting Date for Special Meeting of Stockholders
5. NeuroDerm Announces Presentation of ND0612 Phase 1 and Phase 2 Results at the 2013 International Congress of Parkinsons Disease and Movement Disorders
6. Royalty Pharma Announces Offer May Lapse (Be Withdrawn)
7. Anthera Pharmaceuticals Announces Personnel Changes
8. Generex Announces Interview of MD Andersons Dr. Elizabeth Mittendorf, Principal Investigator on Companys AE37 Phase IIb Breast Cancer Efficacy Trial
9. Amgen Announces Top-Line Results Of Phase 3 Trebananib (AMG 386) TRINOVA-1 Trial In Recurrent Ovarian Cancer
10. HeartWare International Announces Intention To Delist From Australian Securities Exchange (ASX)
11. Misonix, Inc. Announces the Grant of Patent by the United States Patent and Trademark Office
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... N.J. , Oct. 22, 2014  Quest Diagnostics ... of diagnostic information services, today announced that its Board ... serve as a director, effective December 1, 2014. Including ... Dr. Leiden is the Chairman, President and CEO of ... years of scientific and commercial experience in the pharmaceutical ...
(Date:10/22/2014)... 2014  Charlene Vernak, RPh, of Vernak Farms Pharmacy ... was awarded the George Roentsch Scholarship by the Professional ... in Houston during PCCA,s International ... annually to an independent pharmacist and PCCA member who ... Roentsch , a well-known pharmacist in the compounding community. ...
(Date:10/22/2014)... Calif. , Oct. 22, 2014  Paper ... products, has developed APLS ® Body Guard ... minimizes the spread of bacteria and virus while ... APLS Body Guard Bio features a rugged, external ... edges that create a leak-proof inner chamber that ...
Breaking Medicine Technology:Quest Diagnostics Adds Jeffrey M. Leiden, M.D., Ph.D., to Board of Directors 2Quest Diagnostics Adds Jeffrey M. Leiden, M.D., Ph.D., to Board of Directors 3PCCA Awards Charlene Vernak, RPh, the George Roentsch Scholarship 2New, State-Of-The-Art Body Bag Minimizes The Spread Of Bacteria And Virus 2
... , WASHINGTON, Nov. 4 Sanford Wittels & Heisler, ... AtriCure, Inc., a medical device company specializing in cardiac ... with the Department of Justice (DOJ) in a qui ... interest over a five-year period. , Sanford Wittels & ...
... OAKS, Calif., Nov. 4 Amgen (Nasdaq: AMGN ... its 19th annual Amgen Award for Science Teaching Excellence ... honor extraordinary science teachers at the K-12 level who ... who achieve demonstrated results in student learning in communities ...
Cached Medicine Technology:Relator's Attorneys Comment On AtriCure/DOJ Proposed Settlement 2Call for Applications: The Amgen Award for Science Teaching Excellence 2Call for Applications: The Amgen Award for Science Teaching Excellence 3
(Date:10/25/2014)... New York, New York (PRWEB) October 25, 2014 ... of transvaginal mesh lawsuits ( http://www.vaginalmeshlawsuit2015.com/ ) ... multidistrict litigation underway in U.S. District Court, Southern ... Motion for Summary Judgment on Punitive Damages in ... Florida plaintiffs. In a ruling issued on October ...
(Date:10/25/2014)... 25, 2014 Limbkeepers® announced today that ... Innovations with Ed Begley Jr, airing 1st QTR 2015 ... In this episode, Innovations will focus on Limbkeepers® non ... fragile, thinning skin on arms, hands, and legs from ... these versatile products, which help reduce injuries, allow for ...
(Date:10/25/2014)... Steven Reinberg HealthDay ... The virus that causes common cold sores -- herpes simplex ... by Swedish researchers suggest. In fact, being a carrier ... of Alzheimer,s disease, the researchers found. "The identification ... dementia disorder is a breakthrough," said lead researcher Dr. Hugo ...
(Date:10/25/2014)... FRIDAY, Oct. 24, 2014 (HealthDay News) -- Researchers ... say their findings are cause for concern. ... that are raised for human consumption contribute to ... health, according to background information from the study. ... germs sicken about 2 million people and kill ...
(Date:10/25/2014)... News) -- Current osteoporosis screening guidelines and tools ... risk for osteoporosis-related fractures, a new study says. ... need tools that help us accurately predict who ... can target these at-risk people for preventive measures," ... in the division of general internal medicine and ...
Breaking Medicine News(10 mins):Health News:Transvaginal Mesh Lawsuits Move Forward, As Federal Judge Denies Motion for Summary Judgment on Punitive Damages in Florida Cases, Bernstein Liebhard LLP Reports 2Health News:Transvaginal Mesh Lawsuits Move Forward, As Federal Judge Denies Motion for Summary Judgment on Punitive Damages in Florida Cases, Bernstein Liebhard LLP Reports 3Health News:Transvaginal Mesh Lawsuits Move Forward, As Federal Judge Denies Motion for Summary Judgment on Punitive Damages in Florida Cases, Bernstein Liebhard LLP Reports 4Health News:Upcoming Episode of Innovations with Ed Begley, Jr. to Feature Limbkeepers® 2Health News:Studies Link Cold Sore Virus to Alzheimer's Risk 2Health News:Studies Link Cold Sore Virus to Alzheimer's Risk 3Health News:Researchers Say Antibiotics in Fish a Health Concern 2Health News:Osteoporosis Screening Guidelines May Miss Younger Women at Risk 2
... a kind of disability. Researchers at Pope University, have found ... of aged people between 51 and 62.// ,Those ... cent more likely to report disabilities with respect to work ... greater risk. These were people who drank more than three ...
... aspirin because it thins the blood and prevents the ... widely used class of pain relievers known as nonsteroidal ... other aches and pains. The popular pain reliever ibuprofen ... study that sounds a warning for people who take ...
... are infected with HIV every year in the US, with ... of all U.S. patients with the AIDS virus have an ... to treat it. // Drug-resistant HIV had spread faster and ... normal lives were becoming increasingly limited in their usefulness. ...
... offer some protection against adult-onset diabetes.,An expert behind the ... benefit now by adding the spice to their food.// ... more prevalent than insulin-dependent diabetes, which normally begins earlier ... and insulin injections. It happens when cells in the ...
... is responsible for people who find it impossible to stay ... new treatments for jet lag//, insomnia and seasonal depression. ... cannot stay awake much after 8.30pm and who wake up ... advanced sleep-phase syndrome". This means the person's body clock is ...
... they have discovered the Holy Grail of bad smells ... effects of flatulence. American researchers believe the answer to ... that an object called a Toot Trapper, a cushion ... to almost unnoticeable levels. ,The scientists from ...
Cached Medicine News:Health News:Sniff out flatulence, 2
... The ideal system for specimen surface ... with the ultramilling attachment Leica SP2600. ,Ultramilling ... microtomy and saw microtomy in sample preparation. ... soft materials are located side by side ...
ACRYSOF®, Posterior Chamber Intraocular Lenses are indicated for the replacement of the human lens to achieve visual correction of aphakia in patients sixty years and older. These lenses are i...
... USIOL lenses are manufactured using ... processes. Perspex CQ UV PMMA ... multi-piece and single piece lenses. ... in both nonphaco and phaco ...
Multipiece PMMA IOL - Sulcus Fixation....
Medicine Products: